Veltio Pharma AB is a Swedish AB based in Uppsala, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2018, the company reported revenue of SEK 282.2k in its latest annual filing.
Firman tecknas av styrelsen Firman tecknas i förening av Bergström, Jon Daniel Mihranyan, Albert Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva farmaceutisk och biomedicinsk forskning och utveckling och där med förenlig verksamhet.
In its most recent annual report (2025), Veltio Pharma AB reported revenue of SEK 282.2k, an increase of 262% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net loss of SEK 5.2m, and the EBITDA margin stood at -1,742.3%.
At the end of 2025, equity financed 87.3% of the balance sheet, and current assets covered short-term debt 6.5 times.
Frequently asked questions
What is the Org number of Veltio Pharma AB?
Veltio Pharma AB is registered with Bolagsverket / SCB under Org 5591612840.
What is the revenue of Veltio Pharma AB?
Veltio Pharma AB reported revenue of SEK 282.2k in 2025.
Who is the CEO of Veltio Pharma AB?
Lisa Stina Katarina Lundgren is the CEO of Veltio Pharma AB, in role since 2025.
Who is the chairman of Veltio Pharma AB?
Jon Daniel Bergström chairs the board of Veltio Pharma AB, in role since 2022.
